Please assess the completion status of the following clinical trial:

Trial Title: Rituximab for the Treatment of Wegener's Granulomatosis and Microscopic Polyangiitis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Weight of at least 88 pounds(40 kilograms)~* Diagnosis of Wegener's granulomatosis or microscopic polyangiitis according to the definitions of the Chapel Hill Consensus Conference~* Newly diagnosed patient of Wegener's granulomatosis or microscopic polyangiitis OR must be experiencing a disease flare characterized by: (a) active disease with a Birmingham Vasculitis Activity Score for Wegener's granulomatosis (BVAS/WG) of 3 or greater that would normally require treatment with CYC; OR (b) disease severe enough to require treatment with CYC; OR (c) must be positive for either PR3-ANCA (ANCA directed against proteinase 3) or MPO-ANCA (ANCA directed against myeloperoxidase)at the screening~* Willing to use acceptable forms of contraception for the duration of the study and for up to 1 year after stopping study medications~* Willing to report pregnancies (female participants or male participants' partners) occurring at any time during the study and for up to 1 year after stopping study medications~* Parent or guardian willing to provide informed consent, if applicable~Exclusion Criteria:~* Diagnosis of Churg-Strauss Syndrome according to the definitions of the Chapel Hill Consensus Conference~* Have limited disease that would not normally be treated with CYC~* Requires mechanical ventilation because of alveolar hemorrhage~* History of severe allergic reactions to human or chimeric monoclonal antibodies~* Active systemic infection~* Have a deep-space infection, such as osteomyelitis, septic arthritis, or pneumonia complicated by pleural cavity or lung abscess, within 6 months prior to study entry~* History of or current hepatitis B or C infection~* HIV (human immunodeficiency virus) infected~* Acute or chronic liver disease that, in the opinion of the investigator, may interfere with the study~* History of or active cancer diagnosed within the last 5 years. Individuals with squamous cell or basal cell carcinomas of the skin and individuals with cervical carcinoma in situ who have received curative surgical treatment may be eligible for this study.~* History of anti-glomerular basement membrane (anti-GBM) disease~* Other uncontrolled disease, including drug and alcohol abuse, that may interfere with the study~* Pregnancy or breastfeeding

- Gender: ALL
- Minimum Age: 15 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Rituximab (Type: EXPERIMENTAL): None
- Control Group (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).